Overview

Continuous Bioprocessing Market is predicted to value over USD 7 billion by 2027 end with a CAGR of over 8.5% during the forecast period 2020 to 2027.

The rising insistence for biopharmaceutical products, development of advanced technologies pertaining to continuous bioprocessing, bolstered support from government for manufacturing biopharmaceuticals are some of the driving factors contributing to the growth of the market. The consistent production of biopharmaceuticals on a commercial and clinical level with the use of flexible facilities is called continuous bioprocessing.

The continuous bioprocessing market growth is primarily driven by increased development of novel technologies, rising insistence for biopharmaceuticals, increased support from the government for manufacturing biopharmaceuticals. There has been a significant escalation in the occurrence of chronic disorders across the world. As per the American Pharmaceutical Review, the insistence for antibody products has escalated and with the biologic license application, the antibody products account for over 65% of all the biopharmaceutical products. Furthermore, as per the journal, over 80% of the products are in phase 3 of the development stage while over 90% of products are currently in phase 1 and phase 2 of development.

Moreover, with complexities occurring in clinical trials, the financial assistance provided by the government for research and development activities has increased significantly. For instance, the government of India announced the ‘Pharma Vision 2020’ in 2018 and this aims at reducing the time required for approving new sites, thereby escalating the capacity of producing biopharmaceuticals. Additionally, the government has decided to completely favour FDI for the pharmaceutical industry resulting in the rise of collaborations between the government and the pharmaceutical giants. Furthermore, The National Institute of Health of the United States partnered with over 10 biopharma companies in 2017 to announce the ‘Partnership for Accelerating Cancer Therapies’, which is a private-public research collaboration set for five years. This collaboration shall help in developing immunotherapies for cancer with a total investment of over USD 200 million. Moreover, Japan’s Ministry of Health, Labour and Welfare in 2015 announced the ‘Sakigake’ scheme that aimed at accelerating the launch time for novel drugs.

However, high contamination risks pertaining to continuous processing, operational complexities related to continuous processing and a lack of professionals that work into bioprocessing are some of the factors restraining the market growth.

Continuous Bioprocessing Market
Market Segmentation:

By Product

Filtration Systems and Consumables
Chromatography Systems and Consumables
Bioreactors
Cell Culture Media and Reagents
Others

By End User

Pharmaceutical and Biotechnology Companies
Contract Development and Manufacturing Organizations
Academics and Research Institutes

By Region

North America
Europe
Asia-Pacific
Latin America
Middle East and Africa

The global market is fragmented into product, end user and region. The product segment is categorised into filtration systems and consumables, chromatography systems and consumables, bioreactors and cell culture media and reagents. The filtration system and consumables segment held the largest continuous bioprocessing market share owing to rising acceptance of single use filters for the purification of biopharmaceutical products and frequent usage of related products are bolstering the lead of the segment. The end user segment is divided into pharmaceutical and biotechnology companies, contract development and manufacturing organizations and academics and research institutes. The pharmaceutical and biotechnology companies are anticipated to lead the market due to the rising acceptance of products and consumables required for manufacturing biopharmaceuticals by these companies.

Regional Analysis:

The North America region is expected to dominate the market during the forecast period owing to a strong presence of prominent market players in the region and the rising support by the government by assigning funds for research and development of continuous bioprocessing. However, the Asia Pacific region is predicted to grow with a substantial rate over the forecasted timeframe owing to a rise in the occurrence of chronic disorders, increased emphasis of the government in improving the biopharmaceutical industry. Additionally, important business expansions by key market players in the region shall augment the market growth.

Competitive Landscape:

Some of the prominent players of the market are GE Healthcare, Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Bio-Rad Laboratories, Inc., Sartorius AG, Repligen Corporation, Eppendorf AG, 3M Company, Applikon Biotechnology B.V.

FutureWise Key Takeaways:

Growth prospects
SWOT analysis
Key market trends
Key data-points affecting market growth

Objectives of the Study:

To provide with an exhaustive analysis on the global continuous bioprocessing market by product, by end user and by region
To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
To evaluate and forecast micro-markets and the overall market
To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
The customization Mobility Care offered are free of charge with purchase of any license of the report
You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com